- Advertisement -
TAG
Eli Lilly
Eli Lilly earnings beat forecasts as revenue jumps
Eli Lilly earnings rose 39% to $24.4 billion in Q3 2026 as Mounjaro and Zepbound drove growth, and guidance rose to $91-92 billion for 2026.
Retatrutide leads obesity pipeline recall in US survey
Eli Lilly's retatrutide was the most recalled obesity pipeline drug in a Spherix survey, after new TRIUMPH-2 results showed 20.8% weight loss.
